Abstract
Osteoporosis is characterized by skeletal fragility and microarchitectural deterioration. The side effects of drugs to treat osteoporosis will negatively affect the health of patients. This study aimed to investigate the therapeutic effects of icariin combined with adipose-derived stem cells on osteoporosis in a postmenopausal osteoporosis model after ovariectomy in rats. After ovariectomy the rats were treated with icariin combined with adipose-derived stem cell transplantation. The levels of alkaline phosphatase, tartrate-resistant acid phosphatase, osteoprotegerin, and bone γ-carboxyglutamate protein in serum were determined by ELISA. The bone mineral density was measured by dual-energy X-ray absorptiometry. The mechanical properties were determined by a three-point bending test. The kidney functions were evaluated by an automatic analyzer and a diagnostic kit. Icariin combined with stem cells significantly reduced body weight gain caused by ovariectomy, significantly decreased alkaline phosphatase, tartrate-resistant acid phosphatase, and bone γ-carboxyglutamate protein content in serum, significantly increased osteoprotegerin content, significantly elevated bone mineral density of the lumbar spine, left femur, and right femur, and enhanced bone biomechanical properties of the femur, including maximum bending load, bending rigidity, and fracture energy, in osteoporotic rats. In addition, icariin combined with stem cells substantially decreased the damage to the liver and kidney in osteoporotic rats. Icariin combined with stem cells can not only ameliorate reduction of bone mass and disruption of the microarchitectural structure of bone tissue caused by osteoporosis in a rat model but can also have a beneficial effect on organ functions, such as those of the liver and kidney.
Similar content being viewed by others
References
Lindsay R (1993) Pathogenesis of postmenopausal osteoporosis. Baillieres Clin Rheumatol 7:499–513
Edwards BJ, Brooks ER, Langman CB (2004) Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach. Gend Med 1:70–85
Meeta Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2013) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations. J Midlife Health 4:107–126
Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381
Leung PC, Siu WS (2013) Herbal treatment for osteoporosis: a current review. J Tradit Complement Med 3:82–87
Hinton PS, Nigh P, Thyfault J (2015) Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial. Bone 79:203–212
Evans RK, Negus CH, Centi AJ, Spiering BA, Kraemer WJ, Nindl BC (2012) Peripheral QCT sector analysis reveals early exercise induced increases in tibial bone mineral density. J Musculoskelet Neuronal Interact 12:155–164
Bauer DC (2013) Calcium supplements and fracture prevention. N Engl J Med 369:1537–1543
Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683
Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta analysis. J Clin Endocrinol Metab 97:1871–1880
Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Qin L, Zhang G, Hung WY, Shi Y, Leung K, Yeung HY, Leung P (2005) Phytoestrogen rich herb formula “XLGB” prevent OVX-induced deterioration of musculoskeletal tissues. J Bone Miner Metab 23:55–61
Zhang Y, Lai WP, Wong MS (2006) Effects of Fracutus Ligustri Lucidi extract on bone turn over and calcium balance in ovariectomized rats. Biot Pharm Bull 29:291–296
Li GW, Xu Z, Chang SX, Nian H, Wang XY, Qin LD (2014) Icariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesis. Menopause 21:1007–1016
Mao XY, Bian Q, Shen ZY (2012) Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Zhong Xi Yi Jie He Xue Bao 10:1272–1278
Levis S, Theodore GJ (2012) Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Manag Care Pharm 18:S1–15
Black DM (2016) Postmenopausal osteoporosis. N Engl J Med 374:254–262
Kapoor S (2013) Icariin and its emerging role in the treatment osteoporosis. Chin Med J (Engl) 126:400
Liu M, Zhong C, He RX, Chen LF (2012) Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chin Med J (Engl) 125:1784–1789
Zhang G, Qin L, Shi Y (2007) Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double- blind and placebo-controlled trial. J Bone Miner Res 22:1072–1079
Caplan AI (2015) Adult mesenchymal stem cells and women’s health. Menopause 22:131–135
Kwak EJ, Lee YS, Choi EM (2012) Effect of magnolol on the function of osteoblastic MC3T3-E1 cells. Mediat Inflamm 2012:829650
Eastell R, Reid DM, Vukicevic S, Ensrud KE, LaCroix AZ, Thompson JR, Thompson DD, Cummings SR (2012) Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone 50:1135–1140
Mok SK, Chen WF, Lai WP, Leung PC, Wang XL, Yao XS, Wong MS (2010) Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 159:939–949
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declares no conflict of interest.
About this article
Cite this article
Tang, D., Ju, C., Liu, Y. et al. Therapeutic effect of icariin combined with stem cells on postmenopausal osteoporosis in rats. J Bone Miner Metab 36, 180–188 (2018). https://doi.org/10.1007/s00774-017-0831-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-017-0831-x